-
AstraZeneca’s Covid troubles could see it pull out of making vaccinesNews AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
News -
AstraZeneca’s shareholders rebel over payNews Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
News -
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine warsProfiles AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time of it.
Profiles -
If you'd invested in: AstraZeneca and Mitie GroupFeatures Pharmaceutical giant AstraZeneca is expected to grow its earnings, while outsourcer Mitie's share rice has been hit by a series of profit warnings.
Features -
How to profit as Britain piles on the poundsCover Story The world is getting fatter – and with no easy solution to obesity in sight, investing in healthcare providers and food and drink makers could bring big gains, says Jonathan Compton.
Cover Story -
Major setback for AstraZenecaFeatures Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
Features -
A revolutionary new cancer treatment – and the blue-chip stock set to benefitFeatures A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
Features -
The rise of ‘tax inversion’
Features More and more American businesses are snapping up companies in low-tax countries to make that their official home. British companies are in their sights. Simon Wilson reports.
Features -
AstraZeneca fight rumbles onNews The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
News
1
2